Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $1.09, $0.07 better than the analyst estimate of $1.02. Revenue for the quarter came in at $783.9 million versus the consensus estimate of $790.91 million.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.